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Direct medical costs were estimated using tariffs for laboratory tests, diagnostic 
exams, visits, and prices for drugs. Procedure and inpatient cost data were collected 
at Center level. Non medical costs included costs for travel and accommodation, 
domestic help and informal care. The loss of productivity of patients have been 
estimated using the human capital approach. The incremental effects of having 
comorbidities on social costs were estimated by multivariate Generalized Linear 
Models (log link, Gamma family) adjusting for gender, age, BMI, type of interven-
tion and complications. Costs are expressed in Euro 2013. Results: Among 301 
patients enrolled, 108 (36%) had hypertension, 53 (18%) T2DM and 47 (16%) ADD. The 
raw social cost of intervention were € 8,749 (± € 2,359), € 9,511 (± € 2,292) and € 8,999 
(± € 2,275) for patients with hypertension, T2DM and ADD. A significant incremen-
tal effect of having T2DM was found on social cost of intervention (€ 751, 95%CI: 
242-1,259, p= 0.004). 1 year after intervention reductions of 48%, 81% and 15% were 
observed for hypertension, T2DM and ADD. The raw social annual costs estimated 
were € 2,461 (± € 1,490) for hypertension, € 2,424 (± € 951) for T2DM and € 3,582 (± 
€ 2,017) for ADD. Direct non medical costs and indirect costs represent the main 
component of social cost in patients with hypertension and ADD. ConClusions: 
Bariatric surgery led to reductions of obesity-related comorbidities. One year after, 
the economic burden is mainly sustained by patients, their families and the pro-
ductivity system.
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objeCtives: The objective of this study is to estimate the average annual direct 
and indirect costs associated with Duchenne muscular dystrophy (DMD) in Italy 
considering both National Health System (NHS) societal perspective. Methods: 
A probabilistic prevalence-based cost of illness model was used to estimate the 
economic impact of a rare disease as DMD. All the costs were determined through 
a survey that families registered with the Muscular Dystrophy Association “Parent 
Project onlus” completed on-line. NHS and family prospective has been analyzed 
dividing the patients into three age groups (< 8, 8 – 16 and > 16). Human capital 
approach was used to determine loss of productivity due to absenteeism, while the 
bottom up approach was used to calculate direct costs. Furthermore, a probabilistic 
sensitivity analysis with 5,000 Monte Carlo simulations was performed, in order 
to test the robustness of results and define the 95%CI. Results: Indirect costs 
are those that weigh more on the total expenditure of the NHS with € 474.634.836 
(95%CI: € 300.028.168 - € 698.965.090) per year, while the direct health care costs are € 
7.475.596 (95%CI: € 5.124.369,29 - € 10.263.785) and nonmedical costs are € 12.944.879 
(95% CI: € 7.925.699 - € 19.175.331). Patients with more than 16 years spend more 
than those between 0 and 7 years old, and even more than those between 8 and 15. 
For what concern the private expenditure, the model estimated € 2.910.506 (95%CI: 
€ 345.231,83 - € 718.786) for the direct costs, and € 185.333.744 (95%CI: € 114.177.282 
- € 273.446.219) for the nonmedical costs. ConClusions: Although DMD is a rare 
disease, its economic impact on NHS is quite remarkable. Furthermore, the most 
of the impact relies on families and society.
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objeCtives: To estimate the burden of myelofibrosis (MF) in Greece, focusing on 
epidemiological data, quality of life (QoL), direct and indirect costs. Methods: A 
17-page questionnaire was developed, validated, and completed with the Delphi 
technique. It included questions on epidemiological, resource use, QoL and socio-
economic data. An expert panel with 9 KOL haematologists was convened consisting 
of experts from the largest Haematology Units of Greece, covering geographically 
six out of seven Regional Health Authorities. Unit costs in 2014 prices were taken 
from officially published sources. The societal perspective was adopted. Results: 
Prevalence and incidence rates of MF in Greece are approx. 2.5: 100,000 and 0.7: 
100,000 people respectively, corresponding to approx. 270 patients (71.7% with pri-
mary and 28.3% with secondary) and 76 new cases every year; 92% of the patients 
present with splenomegaly at diagnosis, 1/3 of which reduce their daily activi-
ties. Current treatment options in Greece are ruxolitinib and best supportive care 
(BSC). 72.6% of the primary and 65% of the secondary MF patients treated with 
ruxolitinib show improvement of splenomegaly vs. 23% and 7%, respectively for 
patients treated with BSC. Ruxolitinib patients show QoL improvement and less 
splenectomies (< 1%) compared with BSC patients (~3%). Work loss days associated 
with ruxolitinib are estimated at 23 days per year (51 days for BSC), and 20% of them 
return to work after treatment (5% for BSC). The annual direct cost of managing 
all MF patients in Greece is estimated at € 1.65 million, including pharmaceuti-
cal, hospital, follow-up costs, blood transfusions, and management of infections. 
Productivity losses are estimated at € 217,975 per year, resulting in a total annual 
burden of approx. € 1.87 million. ConClusions: MF is associated with significant 
burden to patients, their families, and to the society. Treatment with ruxolitinib 
appears to improve patients’ QoL and reduce indirect costs, mainly through reduc-
tion of splenomegaly and splenectomies.
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and costs (all p< 0.05), the adjusted annual incremental costs in abusers versus non-
abusers were $28,882 (95% Confidence Interval [CI]: $28,455-$29,311) and $15,523 
(95% CI: $15,389-$15,657) per patient among Medicaid and commercially insured 
patients, respectively, during the post-index period. The main cost driver was inpa-
tient hospitalization which comprised 88% of unadjusted incremental costs during 
follow up in Medicaid insured population and 53% in commercial insured popula-
tion. ConClusions: Diagnosed opioid abusers among long-term IR hydrocodone 
users impose significantly higher financial burden in both Medicaid and commer-
cially insured populations in terms of all-cause direct health care expenditures, 
ranging from $28,882 to $15,523 per abuser per year.
PSY38
PrevAlenCe-BASeD MeASureMent of the eConoMIC BurDen of rAre 
DISeASeS: CASe revIeW to DeterMIne the AnnuAl CoSt of ACroMeGAlY 
In ItAlY
Premoli E.1, Tasdemir E.2, Magestro M.3, Griner B.P.4, Cummins G.5, Van Engen A.6, 
Kreeftmeijer J.6, Niemira J.4, Tao C.7
1Novartis Pharma - BU Oncology, Origgio, Italy, 2Novartis Oncology, Origgio / VA, Italy, 3Novartis 
Pharmaceuticals Corporation, East Hanover, NJ, USA, 4Quintiles, Cambridge, MA, USA, 5Quintiles, 
Durham, NC, USA, 6Quintiles Consulting, Hoofddorp, The Netherlands, 7Quintiles Consulting, 
Cambridge, MA, USA
objeCtives: Although acromegaly is acknowledged as requiring resource-intensive 
treatment, its ultimate economic burden is unclear. As an extension of work pre-
sented at ISPOR 2013 International Conference (New Orleans, US), the objective of 
this research is to measure the annual economic burden of acromegaly in Italy using 
a case-review methodology with a prevalence-based sample of patients diagnosed 
with acromegaly. Methods: A case-review method was used with a sample of 22 
endocrinologists reviewing 86 patient cases (4 cases per physician) diagnosed with 
acromegaly. The patient case histories included: resource utilization including office 
visits and hospitalization, diagnostic procedures and labs, medications prescribed, 
medical procedures preformed, and an estimate of lost productivity. A micro-costing 
analysis was conducted to obtain costs in the prior 12 months for each patient case 
reviewed, using published literature, medical fee schedules, and pharmaceutical 
cost databases to assign costs to treatments and medical procedures identified in 
the survey data. Annual costs were examined across a broad range of patients of 
different ages, gender and time from diagnosis. Two biomarkers were used to cat-
egorize acromegaly patients as Controlled vs. Uncontrolled: Insulin Growth Factor-1 
(IGF-1) and Growth Hormone (GH). Several patient characteristics were used as 
control factors when comparing annual economic impact: age, sex, and time from 
diagnosis. Statistical tests and confidence intervals were calculated to determine the 
significance of patient characteristic effects on economic burden. Results: Three 
patient subgroups were used to classify uncontrolled acromegaly patients: IGF-1, 
GH and both IGF-1 and GH. The annual per-patient economic burden of disease 
costs ranges from € 18,600 to € 38,000 across these groups. These cost ranges are 
benchmarked to other studies to provide context and validity. ConClusions: The 
total economic burden acromegaly in Italy is significant. Understanding the factors 
impacting burden of illness will inform future improvements in treatment practice.
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objeCtives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with psoriatic and enteropathic arthropathies from the perspec-
tive of the Social Insurance Institution (ZUS) in Poland. Methods: The estimates 
were based on data published by ZUS referring to year 2012 and concerning absence 
from work due to the illness (sick leave), the amount of short term disability, the 
sufferers of which claim rehabilitation benefit, and the amount of permanent (or 
long term) disability, the sufferers of which claim disability pension. Costs were 
calculated with Human Capital Approach methodology taking into account Gross 
Domestic Product (GDP) per capita equaled 41 398 PLN; results were presented 
in Polish zloty (PLN). Results: Total indirect costs of psoriatic and enteropathic 
arthropathies in the year 2012 calculated using GDP per capita in Poland were 9 
312 773 PLN. The highest component of indirect costs of psoriatic and enteropathic 
arthropathies was sick leave (82%). Long and short term disability costs consti-
tute 9% and 8% of total indirect costs of psoriatic and enteropathic arthropathies, 
respectively. In 2012 Poland’s Social Insurance Institution database reported 1 900 
patients on sick leave, 54 patients with short term disability and 3 patients with 
long term disability. Indirect costs per patient associated with sick leave were 4 
037 PLN calculated using GDP per capita. Indirect costs per patient associated with 
short term disability were as high as 16 227 PLN and associated with long term 
disability were as high as 255 288 PLN. ConClusions: Psoriatic and enteropathic 
arthropathies in Poland generated high indirect costs. The main component was 
sick leave; rehabilitation benefit and disability pension generated much lower costs 
of lost productivity.
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objeCtives: To estimate the social cost of bariatric surgery techniques in obese 
patients with hypertension, diabetes mellitus (T2DM) and anxiety-depression disor-
ders (ADD). Methods: A longitudinal multicenter study was conducted by enroll-
ing obese adult patients in charge to 6 Hospital in Italy at time of intervention of 
gastric banding, gastric by-pass, and sleeve gastrectomy and following up to 1 year. 
